A	O
Variant	B:C0678941
in	O
the	O
BACH2	O
Gene	I:C1422394
Is	O
Associated	O
With	O
Susceptibility	O
to	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
Disease	I:C0271737
in	O
Humans	O
.	O

A	O
Variant	O
in	O
the	O
BACH2	B:C1422394
Gene	I:C1422394
Is	O
Associated	O
With	O
Susceptibility	O
to	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
Disease	I:C0271737
in	O
Humans	O
.	O

A	O
Variant	O
in	O
the	O
BACH2	O
Gene	I:C1422394
Is	O
Associated	O
With	O
Susceptibility	B:C0012655
to	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
Disease	I:C0271737
in	O
Humans	O
.	O

A	O
Variant	O
in	O
the	O
BACH2	O
Gene	I:C1422394
Is	O
Associated	O
With	O
Susceptibility	O
to	O
Autoimmune	B:C0271737
Addison	I:C0271737
's	I:C0271737
Disease	I:C0271737
in	O
Humans	O
.	O

A	O
Variant	O
in	O
the	O
BACH2	O
Gene	I:C1422394
Is	O
Associated	O
With	O
Susceptibility	O
to	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
Disease	I:C0271737
in	O
Humans	B:C0086418
.	O

Autoimmune	B:C0271737
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
(	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
)	O
is	O
a	O
rare	O
but	O
highly	O
heritable	I:C0019247
condition	I:C0019247
.	O

Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
(	O
Autoimmune	B:C0271737
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
)	O
is	O
a	O
rare	O
but	O
highly	O
heritable	I:C0019247
condition	I:C0019247
.	O

Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
(	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
)	O
is	O
a	O
rare	O
but	O
highly	B:C0019247
heritable	I:C0019247
condition	I:C0019247
.	O

The	O
BACH2	B:C1453878
protein	I:C1453878
plays	O
a	O
crucial	O
role	O
in	O
T	O
lymphocyte	I:C2246791
maturation	I:C2246791
,	O
and	O
allelic	O
variation	O
in	O
its	O
gene	O
has	O
been	O
associated	O
with	O
a	O
number	O
of	O
autoimmune	O
conditions	I:C0004368
.	O

The	O
BACH2	O
protein	I:C1453878
plays	O
a	O
crucial	O
role	O
in	O
T	B:C2246791
lymphocyte	I:C2246791
maturation	I:C2246791
,	O
and	O
allelic	O
variation	O
in	O
its	O
gene	O
has	O
been	O
associated	O
with	O
a	O
number	O
of	O
autoimmune	O
conditions	I:C0004368
.	O

The	O
BACH2	O
protein	I:C1453878
plays	O
a	O
crucial	O
role	O
in	O
T	O
lymphocyte	I:C2246791
maturation	I:C2246791
,	O
and	O
allelic	O
variation	O
in	O
its	O
gene	B:C0017337
has	O
been	O
associated	O
with	O
a	O
number	O
of	O
autoimmune	O
conditions	I:C0004368
.	O

The	O
BACH2	O
protein	I:C1453878
plays	O
a	O
crucial	O
role	O
in	O
T	O
lymphocyte	I:C2246791
maturation	I:C2246791
,	O
and	O
allelic	O
variation	O
in	O
its	O
gene	O
has	O
been	O
associated	O
with	O
a	O
number	O
of	O
autoimmune	B:C0004368
conditions	I:C0004368
.	O

We	O
aimed	O
to	O
determine	O
whether	O
alleles	B:C0002085
of	O
the	O
rs3757247	O
single	I:C0752046
nucleotide	I:C0752046
polymorphism	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphism	I:C0752046
)	O
in	O
the	O
BACH2	O
gene	I:C1422394
are	O
associated	O
with	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
.	O

We	O
aimed	O
to	O
determine	O
whether	O
alleles	O
of	O
the	O
rs3757247	B:C0752046
single	I:C0752046
nucleotide	I:C0752046
polymorphism	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphism	I:C0752046
)	O
in	O
the	O
BACH2	O
gene	I:C1422394
are	O
associated	O
with	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
.	O

We	O
aimed	O
to	O
determine	O
whether	O
alleles	O
of	O
the	O
rs3757247	O
single	I:C0752046
nucleotide	I:C0752046
polymorphism	I:C0752046
(	O
single	B:C0752046
nucleotide	I:C0752046
polymorphism	I:C0752046
)	O
in	O
the	O
BACH2	O
gene	I:C1422394
are	O
associated	O
with	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
.	O

We	O
aimed	O
to	O
determine	O
whether	O
alleles	O
of	O
the	O
rs3757247	O
single	I:C0752046
nucleotide	I:C0752046
polymorphism	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphism	I:C0752046
)	O
in	O
the	O
BACH2	B:C1422394
gene	I:C1422394
are	O
associated	O
with	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
.	O

We	O
aimed	O
to	O
determine	O
whether	O
alleles	O
of	O
the	O
rs3757247	O
single	I:C0752046
nucleotide	I:C0752046
polymorphism	I:C0752046
(	O
single	O
nucleotide	I:C0752046
polymorphism	I:C0752046
)	O
in	O
the	O
BACH2	O
gene	I:C1422394
are	O
associated	O
with	O
Autoimmune	B:C0271737
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
.	O

This	O
case	B:C0007328
-	I:C0007328
control	I:C0007328
association	I:C0007328
study	I:C0007328
was	O
performed	O
in	O
two	O
phases	O
using	O
Taqman	O
chemistry	I:C1510438
.	O

This	O
case	O
-	I:C0007328
control	I:C0007328
association	I:C0007328
study	I:C0007328
was	O
performed	O
in	O
two	O
phases	O
using	O
Taqman	B:C1510438
chemistry	I:C1510438
.	O

In	O
the	O
first	O
phase	O
,	O
the	O
rs3757247	B:C0752046
SNP	I:C0752046
was	O
genotyped	O
in	O
358	O
UK	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
subjects	O
and	O
166	O
local	O
control	O
subjects	O
.	O

In	O
the	O
first	O
phase	O
,	O
the	O
rs3757247	O
SNP	I:C0752046
was	O
genotyped	O
in	O
358	O
UK	O
Autoimmune	B:C0271737
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
subjects	O
and	O
166	O
local	O
control	O
subjects	O
.	O

In	O
the	O
first	O
phase	O
,	O
the	O
rs3757247	O
SNP	I:C0752046
was	O
genotyped	O
in	O
358	O
UK	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
subjects	B:C0080105
and	O
166	O
local	O
control	O
subjects	O
.	O

In	O
the	O
first	O
phase	O
,	O
the	O
rs3757247	O
SNP	I:C0752046
was	O
genotyped	O
in	O
358	O
UK	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
subjects	O
and	O
166	O
local	O
control	O
subjects	B:C0080105
.	O

Genotype	O
data	O
were	O
also	O
available	O
from	O
5154	O
healthy	O
UK	O
controls	O
from	O
the	O
Wellcome	B:C0007328
Trust	I:C0007328
(	I:C0007328
WTCCC2	I:C0007328
)	I:C0007328
for	O
comparison	O
.	O

In	O
the	O
second	O
phase	O
,	O
the	O
single	B:C0752046
nucleotide	I:C0752046
polymorphism	I:C0752046
was	O
genotyped	O
in	O
a	O
validation	O
cohort	I:C0599755
comprising	O
317	O
Norwegian	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
subjects	O
and	O
365	O
controls	O
.	O

In	O
the	O
second	O
phase	O
,	O
the	O
single	O
nucleotide	I:C0752046
polymorphism	I:C0752046
was	O
genotyped	O
in	O
a	O
validation	B:C0599755
cohort	I:C0599755
comprising	O
317	O
Norwegian	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
subjects	O
and	O
365	O
controls	O
.	O

In	O
the	O
second	O
phase	O
,	O
the	O
single	O
nucleotide	I:C0752046
polymorphism	I:C0752046
was	O
genotyped	O
in	O
a	O
validation	O
cohort	I:C0599755
comprising	O
317	O
Norwegian	B:C0337812
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
subjects	O
and	O
365	O
controls	O
.	O

In	O
the	O
second	O
phase	O
,	O
the	O
single	O
nucleotide	I:C0752046
polymorphism	I:C0752046
was	O
genotyped	O
in	O
a	O
validation	O
cohort	I:C0599755
comprising	O
317	O
Norwegian	O
Autoimmune	B:C0271737
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
subjects	O
and	O
365	O
controls	O
.	O

In	O
the	O
second	O
phase	O
,	O
the	O
single	O
nucleotide	I:C0752046
polymorphism	I:C0752046
was	O
genotyped	O
in	O
a	O
validation	O
cohort	I:C0599755
comprising	O
317	O
Norwegian	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
subjects	B:C0080105
and	O
365	O
controls	O
.	O

The	O
frequency	O
of	O
the	O
minor	B:C0002085
T	I:C0002085
allele	I:C0002085
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
from	O
the	O
United	O
Kingdom	I:C0041700
compared	O
to	O
both	O
the	O
local	O
and	O
WTCCC2	O
control	I:C0599755
cohorts	I:C0599755
(	O
58	O
%	O
vs	O
45	O
and	O
48	O
%	O
,	O
respectively	O
)	O
(	O
local	O
controls	O
,	O
P	O
=	O
1.1	O
×	O
10	O
(	O
-	O
4	O
)	O
;	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.68	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.29	O
-2.18	O
;	O
WTCCC2	O
controls	O
,	O
P	O
=	O
1.4	O
×	O
10	O
(	O
-6	O
)	O
;	O
OR	O
,	O
1.44	O
;	O
95	O
%	O
CI	O
,	O
1.23	O
-1.69	O
)	O
.	O

The	O
frequency	O
of	O
the	O
minor	O
T	I:C0002085
allele	I:C0002085
was	O
significantly	O
higher	O
in	O
subjects	B:C0080105
with	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
from	O
the	O
United	O
Kingdom	I:C0041700
compared	O
to	O
both	O
the	O
local	O
and	O
WTCCC2	O
control	I:C0599755
cohorts	I:C0599755
(	O
58	O
%	O
vs	O
45	O
and	O
48	O
%	O
,	O
respectively	O
)	O
(	O
local	O
controls	O
,	O
P	O
=	O
1.1	O
×	O
10	O
(	O
-	O
4	O
)	O
;	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.68	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.29	O
-2.18	O
;	O
WTCCC2	O
controls	O
,	O
P	O
=	O
1.4	O
×	O
10	O
(	O
-6	O
)	O
;	O
OR	O
,	O
1.44	O
;	O
95	O
%	O
CI	O
,	O
1.23	O
-1.69	O
)	O
.	O

The	O
frequency	O
of	O
the	O
minor	O
T	I:C0002085
allele	I:C0002085
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
Autoimmune	B:C0271737
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
from	O
the	O
United	O
Kingdom	I:C0041700
compared	O
to	O
both	O
the	O
local	O
and	O
WTCCC2	O
control	I:C0599755
cohorts	I:C0599755
(	O
58	O
%	O
vs	O
45	O
and	O
48	O
%	O
,	O
respectively	O
)	O
(	O
local	O
controls	O
,	O
P	O
=	O
1.1	O
×	O
10	O
(	O
-	O
4	O
)	O
;	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.68	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.29	O
-2.18	O
;	O
WTCCC2	O
controls	O
,	O
P	O
=	O
1.4	O
×	O
10	O
(	O
-6	O
)	O
;	O
OR	O
,	O
1.44	O
;	O
95	O
%	O
CI	O
,	O
1.23	O
-1.69	O
)	O
.	O

The	O
frequency	O
of	O
the	O
minor	O
T	I:C0002085
allele	I:C0002085
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
from	O
the	O
United	B:C0041700
Kingdom	I:C0041700
compared	O
to	O
both	O
the	O
local	O
and	O
WTCCC2	O
control	I:C0599755
cohorts	I:C0599755
(	O
58	O
%	O
vs	O
45	O
and	O
48	O
%	O
,	O
respectively	O
)	O
(	O
local	O
controls	O
,	O
P	O
=	O
1.1	O
×	O
10	O
(	O
-	O
4	O
)	O
;	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.68	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.29	O
-2.18	O
;	O
WTCCC2	O
controls	O
,	O
P	O
=	O
1.4	O
×	O
10	O
(	O
-6	O
)	O
;	O
OR	O
,	O
1.44	O
;	O
95	O
%	O
CI	O
,	O
1.23	O
-1.69	O
)	O
.	O

The	O
frequency	O
of	O
the	O
minor	O
T	I:C0002085
allele	I:C0002085
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
from	O
the	O
United	O
Kingdom	I:C0041700
compared	O
to	O
both	O
the	O
local	O
and	O
WTCCC2	B:C0599755
control	I:C0599755
cohorts	I:C0599755
(	O
58	O
%	O
vs	O
45	O
and	O
48	O
%	O
,	O
respectively	O
)	O
(	O
local	O
controls	O
,	O
P	O
=	O
1.1	O
×	O
10	O
(	O
-	O
4	O
)	O
;	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.68	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.29	O
-2.18	O
;	O
WTCCC2	O
controls	O
,	O
P	O
=	O
1.4	O
×	O
10	O
(	O
-6	O
)	O
;	O
OR	O
,	O
1.44	O
;	O
95	O
%	O
CI	O
,	O
1.23	O
-1.69	O
)	O
.	O

This	O
finding	O
was	O
replicated	O
in	O
the	O
Norwegian	B:C0086027
validation	I:C0086027
cohort	I:C0086027
(	O
P	O
=	O
.0015	O
;	O
OR	O
,	O
1.41	O
;	O
95	O
%	O
CI	O
,	O
1.14	O
-1.75	O
)	O
.	O

Subgroup	B:C0936012
analysis	I:C0936012
showed	O
that	O
this	O
association	O
is	O
present	O
in	O
subjects	O
with	O
both	O
isolated	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
(	O
OR	O
,	O
1.53	O
;	O
95	O
%	O
CI	O
,	O
1.22	O
-1.92	O
)	O
and	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
(	O
OR	O
,	O
1.37	O
;	O
95	O
%	O
CI	O
,	O
1.12	O
-	O
1.69	O
)	O
in	O
the	O
UK	O
cohort	I:C0599755
,	O
and	O
with	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
in	O
the	O
Norwegian	O
cohort	I:C0599755
(	O
OR	O
,	O
1.58	O
;	O
95	O
%	O
CI	O
,	O
1.22-2.06	O
)	O
.	O

Subgroup	O
analysis	I:C0936012
showed	O
that	O
this	O
association	B:C0449380
is	O
present	O
in	O
subjects	O
with	O
both	O
isolated	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
(	O
OR	O
,	O
1.53	O
;	O
95	O
%	O
CI	O
,	O
1.22	O
-1.92	O
)	O
and	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
(	O
OR	O
,	O
1.37	O
;	O
95	O
%	O
CI	O
,	O
1.12	O
-	O
1.69	O
)	O
in	O
the	O
UK	O
cohort	I:C0599755
,	O
and	O
with	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
in	O
the	O
Norwegian	O
cohort	I:C0599755
(	O
OR	O
,	O
1.58	O
;	O
95	O
%	O
CI	O
,	O
1.22-2.06	O
)	O
.	O

Subgroup	O
analysis	I:C0936012
showed	O
that	O
this	O
association	O
is	O
present	O
in	O
subjects	B:C0080105
with	O
both	O
isolated	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
(	O
OR	O
,	O
1.53	O
;	O
95	O
%	O
CI	O
,	O
1.22	O
-1.92	O
)	O
and	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
(	O
OR	O
,	O
1.37	O
;	O
95	O
%	O
CI	O
,	O
1.12	O
-	O
1.69	O
)	O
in	O
the	O
UK	O
cohort	I:C0599755
,	O
and	O
with	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
in	O
the	O
Norwegian	O
cohort	I:C0599755
(	O
OR	O
,	O
1.58	O
;	O
95	O
%	O
CI	O
,	O
1.22-2.06	O
)	O
.	O

Subgroup	O
analysis	I:C0936012
showed	O
that	O
this	O
association	O
is	O
present	O
in	O
subjects	O
with	O
both	O
isolated	O
Autoimmune	B:C0271737
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
(	O
OR	O
,	O
1.53	O
;	O
95	O
%	O
CI	O
,	O
1.22	O
-1.92	O
)	O
and	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
(	O
OR	O
,	O
1.37	O
;	O
95	O
%	O
CI	O
,	O
1.12	O
-	O
1.69	O
)	O
in	O
the	O
UK	O
cohort	I:C0599755
,	O
and	O
with	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
in	O
the	O
Norwegian	O
cohort	I:C0599755
(	O
OR	O
,	O
1.58	O
;	O
95	O
%	O
CI	O
,	O
1.22-2.06	O
)	O
.	O

Subgroup	O
analysis	I:C0936012
showed	O
that	O
this	O
association	O
is	O
present	O
in	O
subjects	O
with	O
both	O
isolated	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
(	O
OR	O
,	O
1.53	O
;	O
95	O
%	O
CI	O
,	O
1.22	O
-1.92	O
)	O
and	O
autoimmune	B:C0085860
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
(	O
OR	O
,	O
1.37	O
;	O
95	O
%	O
CI	O
,	O
1.12	O
-	O
1.69	O
)	O
in	O
the	O
UK	O
cohort	I:C0599755
,	O
and	O
with	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
in	O
the	O
Norwegian	O
cohort	I:C0599755
(	O
OR	O
,	O
1.58	O
;	O
95	O
%	O
CI	O
,	O
1.22-2.06	O
)	O
.	O

Subgroup	O
analysis	I:C0936012
showed	O
that	O
this	O
association	O
is	O
present	O
in	O
subjects	O
with	O
both	O
isolated	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
(	O
OR	O
,	O
1.53	O
;	O
95	O
%	O
CI	O
,	O
1.22	O
-1.92	O
)	O
and	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
(	O
OR	O
,	O
1.37	O
;	O
95	O
%	O
CI	O
,	O
1.12	O
-	O
1.69	O
)	O
in	O
the	O
UK	B:C0599755
cohort	I:C0599755
,	O
and	O
with	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
in	O
the	O
Norwegian	O
cohort	I:C0599755
(	O
OR	O
,	O
1.58	O
;	O
95	O
%	O
CI	O
,	O
1.22-2.06	O
)	O
.	O

Subgroup	O
analysis	I:C0936012
showed	O
that	O
this	O
association	O
is	O
present	O
in	O
subjects	O
with	O
both	O
isolated	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
(	O
OR	O
,	O
1.53	O
;	O
95	O
%	O
CI	O
,	O
1.22	O
-1.92	O
)	O
and	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
(	O
OR	O
,	O
1.37	O
;	O
95	O
%	O
CI	O
,	O
1.12	O
-	O
1.69	O
)	O
in	O
the	O
UK	O
cohort	I:C0599755
,	O
and	O
with	O
autoimmune	B:C0085860
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
in	O
the	O
Norwegian	O
cohort	I:C0599755
(	O
OR	O
,	O
1.58	O
;	O
95	O
%	O
CI	O
,	O
1.22-2.06	O
)	O
.	O

Subgroup	O
analysis	I:C0936012
showed	O
that	O
this	O
association	O
is	O
present	O
in	O
subjects	O
with	O
both	O
isolated	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
(	O
OR	O
,	O
1.53	O
;	O
95	O
%	O
CI	O
,	O
1.22	O
-1.92	O
)	O
and	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
(	O
OR	O
,	O
1.37	O
;	O
95	O
%	O
CI	O
,	O
1.12	O
-	O
1.69	O
)	O
in	O
the	O
UK	O
cohort	I:C0599755
,	O
and	O
with	O
autoimmune	O
polyglandular	I:C0085860
syndrome	I:C0085860
type	I:C0085860
2	I:C0085860
in	O
the	O
Norwegian	B:C0599755
cohort	I:C0599755
(	O
OR	O
,	O
1.58	O
;	O
95	O
%	O
CI	O
,	O
1.22-2.06	O
)	O
.	O

We	O
have	O
demonstrated	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
allelic	O
variability	O
at	O
the	O
BACH2	B:C1422394
locus	O
is	O
associated	O
with	O
susceptibility	O
to	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
.	O

We	O
have	O
demonstrated	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
allelic	O
variability	O
at	O
the	O
BACH2	O
locus	B:C1708726
is	O
associated	O
with	O
susceptibility	O
to	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
.	O

We	O
have	O
demonstrated	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
allelic	O
variability	O
at	O
the	O
BACH2	O
locus	O
is	O
associated	O
with	O
susceptibility	B:C0012655
to	O
Autoimmune	O
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
.	O

We	O
have	O
demonstrated	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
allelic	O
variability	O
at	O
the	O
BACH2	O
locus	O
is	O
associated	O
with	O
susceptibility	O
to	O
Autoimmune	B:C0271737
Addison	I:C0271737
's	I:C0271737
disease	I:C0271737
.	O

Given	O
its	O
association	O
with	O
multiple	B:C0004368
autoimmune	I:C0004368
conditions	I:C0004368
,	O
BACH2	O
can	O
be	O
considered	O
a	O
"	O
universal	I:C0243095
"	I:C0243095
autoimmune	I:C0243095
susceptibility	I:C0243095
locus	O
.	O

Given	O
its	O
association	O
with	O
multiple	O
autoimmune	I:C0004368
conditions	I:C0004368
,	O
BACH2	B:C1422394
can	O
be	O
considered	O
a	O
"	O
universal	I:C0243095
"	I:C0243095
autoimmune	I:C0243095
susceptibility	I:C0243095
locus	O
.	O

Given	O
its	O
association	O
with	O
multiple	O
autoimmune	I:C0004368
conditions	I:C0004368
,	O
BACH2	O
can	O
be	O
considered	O
a	O
"	B:C0243095
universal	I:C0243095
"	I:C0243095
autoimmune	I:C0243095
susceptibility	I:C0243095
locus	O
.	O

Given	O
its	O
association	O
with	O
multiple	O
autoimmune	I:C0004368
conditions	I:C0004368
,	O
BACH2	O
can	O
be	O
considered	O
a	O
"	O
universal	I:C0243095
"	I:C0243095
autoimmune	I:C0243095
susceptibility	I:C0243095
locus	B:C1708726
.	O

